Inclusion Criteria:  HIV-1 documented infection; Aged 18 years or older at the time of signing the informed consent;  Stable INSTI-based first-line three-drug ART (switch between different NRTIs are allowed; e.g. from TDF/FTC to TAF/FTC or ABC/3TC, from TAF/FTC to TDF/FTC or ABC/3TC, from ABC/3TC to TAF/FTC or TDF/FTC). Any change of INSTI will not be allowed. Only the following regimens will be allowed:  RAL 1200 mg QD plus TDF/FTC or TAF/FTC; RAL 1200 mg QD plus ABC/3TC; EVG/COBI/FTC/TDF or EVG/COBI/FTC/TAF; DTG plus TDF/FTC or TAF/FTC; DTG/ABC/3TC or DTG plus ABC/3TC; BIC/TAF/FTC Previous INSTI-based first-line ART lasting less than 18 months before screening; To have reached a HIV-1 RNA <50 copies/mL during INSTI first-line therapy for less than 12 months. At least a single HIV-1 RNA determination below the threshold within the 6 months before enrollment is required (if a following determination in present, this should not be ≥50 copies (cp)/mL) HIV-1 RNA below 50 copies/mL at the screening visit; No known allergy or intolerance to the study drugs or their components or drugs of their class;  A female person is eligible to enter the study if it is confirmed that she is:  Not pregnant confirmed by a negative serum pregnancy test at both Screening and Day1; Not breastfeeding; Of non-childbearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy; Of childbearing potential and agrees to utilize the protocol specified method of contraception (as defined in Appendix 1 -Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential) or be non-heterosexually active or practice sexual abstinence (defined as complete abstinence from penile-vaginal intercourse; periodic abstinence, e.g. calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception) from screening throughout the duration of study treatment and for at least two weeks following discontinuation of study drugs; Being able to comply with the protocol requirements and restrictions; Signature of written Informed Consent Form (participants or legal guardian) before that any protocol-specified assessments are conducted.  Exclusion Criteria:  A person will be considered not eligible for inclusion in this study if any of the following criteria apply:  Having failed virologically; Having changed the INSTI drug; Any major INSTI- or NRTI-resistance-associated mutation documented before starting ART; Women who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study;  Evidence of Hepatitis B virus (HBV) infection based on the results of testing at screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-Hbc), hepatitis B surface antigen antibody (anti-HBs) and, possibly, HBV DNA as follows:  Individuals positive for HBsAg are excluded; Individuals negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded; HCV-RNA positivity needing for any hepatitis C virus (HCV) therapy during the study; Ongoing malignancy other than cutaneous Kaposi's sarcoma (not requiring systemic therapy), basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia; Active opportunistic infections requiring active treatment; Creatinine clearance of <50 mL/min/1.73m2 via CKD-EPI method; Individuals with severe hepatic impairment (Child Pugh class C) and/or unstable liver disease; Any verified Grade 4 laboratory abnormality at screening assessment; Alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN) or ALT >3xULN and bilirubin >1.5xULN (with >35% direct bilirubin) at screening assessment; Receipt of investigational research agents within 30 days prior to study entry; Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening; Receipt of immunosuppressive medications or immune-modulators within the past 6 months; Individuals who in the investigator's judgment, poses a significant suicidality risk or with diagnosed major depression, Bipolar Disorders and Psychoses A life expectancy estimated as less than 2 years.